STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?

ABSTRACT: Ovarian carcinoma histotypes are distinct diseases with variable clinical outcomes and response to treatment. There is a need for new subtype-specific treatment modalities, especially for women with widespread and chemo-resistant disease. Stimulator of interferon genes (STING) is a part of the cGAS-STING pathway that mediates innate immune defence against infectious DNA-containing pathogens and also detects tumour-derived DNA and generates intrinsic antitumour immunity. The STING signalling pathway is suppressed by several mechanisms in a variety of malignant diseases and, in some cancers that may be a requirement for cellular transformation. The aim of this study was to use immunohistochemistry to evaluate STING protein expression across normal tissue, paratubal and ovarian cysts, and ova

SUBMITTER: Huvila J 

PROVIDER: S-EPMC8503889 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature